Arkis Biosciences Financing
Arkis Biosciences Inc., Corporation just submitted form D regarding $3.35 million equity financing. This is a new filing. Arkis Biosciences was able to finance itself with $2.33 million so far. That is 69.35% of the financing offer. The total offering amount was $3.35 million. The financing form was filed on 2016-07-11. The reason for the financing was: unspecified. The fundraising still has about $1.03 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Arkis Biosciences is based in Tennessee. The filler’s business is Biotechnology. The form D was filed by Chad E Seaver President and Chief Executive Officer. The company was incorporated in 2016. The filler’s address is: 1059 N. Cedar Bluff Road, #157, Knoxville, Tn, Tennessee, 37923-2233. Chad E. Seaver is the related person in the form and it has address: 1059 N. Cedar Bluff Road, #157, Knoxville, Tn, Tennessee, 37923-2233. Link to Arkis Biosciences Filing: 000167918816000002.
Analysis of Arkis Biosciences Offering
On average, firms in the Biotechnology sector, sell 73.77% of the total offering amount. Arkis Biosciences sold 69.35% of the offering. The fundraising is still open. The average offering amount for companies in the Biotechnology industry is $3.08 million. The offering was 24.51% smaller than the average of $3.08 million. Of course this should not be interpreted as negative. Companies raise funds for a variety of needs and reasons. The minimum investment for this fundraising is set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Arkis Biosciences Also
The Form D signed by Chad E Seaver might help Arkis Biosciences Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.